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PrediabetesDiabetes mellitus is associated with increased risk for cardiovascular disorders, which are major causes of
mortality in this disease. Hyperhomocysteinemia, deﬁned by high plasma homocysteine levels, is an
independent risk factor for the development of cardiovascular diseases. Type 2 diabetic patients have higher
circulating homocysteine levels than healthy subjects and these levels are even higher in plasma of obese than
nonobese diabetic patients. Homocysteine metabolism that has been studied in 2 animal models of type 2
diabetes with obesity led to conﬂicting data. The aim of the present study was to analyze homocysteine
metabolism in a spontaneous nonobese model of type 2 diabetes, the Goto–Kakizaki rats at various successive
and well characterized stages of the disease: during early postnatal normoglycemia, at the onset of
hyperglycemia (aroundweaning), and during chronicmild hyperglycemia with progressive insulin resistance.
Compared to age-matched Wistar controls, Goto–Kakizaki rats showed lower plasma levels of homocysteine
and a falling trend in its major byproduct antioxidant, glutathione, from the prediabetic stage onwards.
Concomitantly, Goto–Kakizaki rats exhibited increased liver activity of cystathionine beta synthase, which
catalyzes the condensation of homocysteinewith serine in the ﬁrst step of the transsulfuration pathway. These
results emphasize a strong association between homocysteine metabolism and insulin via the ﬁrst step of
the hepatic transsulfuration pathway in Goto–Kakizaki rats., 5,5′-dithiobis-(2-nitrobenzoic
ysteine; HFS, high-fat-sucrose;
fatty
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Cardiovascular diseases are the major cause of death in diabetic
patients [1]. Hyperhomocysteinemia, deﬁned by high plasma homo-
cysteine (Hcy) levels, is now well recognized as an independent risk
factor for the development of cardiovascular diseases [2]. Hcy, an
intermediate in the sulfur amino acid metabolism [3], is metabolized
by remethylation to methionine or transsulfuration to cysteine.
Cystathionine beta synthase (CBS), the ﬁrst enzyme involved in the
transsulfuration pathway, catalyzes the condensation of Hcy with
serine to form cystathionine. Cystathionine is subsequently hydro-
lyzed to form cysteine and cysteine, in turn, can be incorporated into
protein, or used to synthesize the antioxidant glutathione (GSH)via the γ-glutamyl cycle. GHS is either used as cellular antioxidant
or exported and becomes a substrate for γ-glutamyl transpeptidase.
The action of γ-glutamyl transpeptidase leads to the formation of
cysteinylglycine,which is subsequently cleaved by dipeptidase to form
cysteine and glycine. Cysteine can then be transported into the cell and
thus be again used for GSH synthesis.
The relationship between diabetes and plasma Hcy levels has been
studied in bothhumans and rodents. PlasmaHcy levels have been found
to be higher in type 2 diabetic patients than in healthy subjects and also,
among type 2 diabetic patients, in obese than in nonobese individuals
[4]. By contrast, reduced serum Hcy levels were described in type 2
diabetic patients without cardiovascular complications or diabetic
nephropathy [5]. Chronic hyperglycemia was thus suggested to affect
its renal excretion, or accelerate hepatic transsulfuration secondary to
insulin disorders [5]. Moreover, subjects with insulin resistance had
signiﬁcantly lower serum Hcy levels compared with non-insulin
resistant subjects [6]. Animal models of type 2 diabetes were then
used to better understand the relationship between insulin resistance
and/or hyperglycemia and circulating Hcy levels. In long-term fed rats
with a high-fat-sucrose (HFS) diet, which induces hyperinsulinemia,
Fig. 1. Age-dependent changes in body weight, and in basal plasma glucose and insulin
levels in GK and Wistar rats. Postnatal growth (A). Glucose (B) and insulin (C) levels
were determined.*pb0.05, **pb0.005, ***pb0.0005 versus age-matched Wistar group.
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were higher than in control rats fed at low-fat, low-carbohydrate diet
[7]. The Zucker diabetic fatty (ZDF) rat is a spontaneous type 2 diabetic
obese animal model characterized by a prediabetic insulin-resistant
stage followed by a rapid transition to frank hyperglycemic stage due
to relative hypoinsulinemia. In the ZDF rat, plasma Hcy levels were
reduced at both prediabetic and diabetic stages, compared to respective
control groups [8]. Thus, conﬂicting data were observed in 2 rat models
of type 2 diabetes with obesity.
The Goto–Kakizaki (GK) rat is another spontaneous and well
characterized but nonobese model of type 2 diabetes [9]. In this
model, a normoglycemic period, which associates low insulinemia
but elevated whole body insulin sensitivity precedes onset of
hyperglycemia around weaning [10]. The aim of the present study
was to analyze Hcy metabolism at 4 crucial steps of the GK rat life:
in normoglycemic 2-week-old neonates and at 1 month of age (onset
of hyperglycemia), and 2 of 3 months of age (aggravation of insulin
resistance) [11].
2. Materials and methods
2.1. Rats
All animal care was conducted in accordance with internal
guidelines of the French Agriculture Ministry for animal handling.
Rats were housed in a controlled environment with unlimited access
to food and water on a 12-h light/dark cycle. Number of rats and
sufferingwereminimized asmuch as possible. All animal experiments
were conducted on age-matched male Goto–Kakizaki (GK) and
nondiabetic (control) Wistar rats from our laboratory [11]. The GK
line was established by repeated inbreeding fromWistar rats selected
at the upper limit of normal distribution for glucose tolerance [9,11].
2.2. Blood, tissue collection and assays
Male rats were weighed, killed by decapitation and blood samples
were collected and placed on ice immediately. Basal fed morning
glycemia was determined with a glucometer. Plasma was isolated by
centrifugation at 2500g for 15 min at 4 °C. Livers were harvested,
snap-frozen and stored at −80 °C until use. Plasma total Hcy (tHcy),
deﬁned as the total concentration of Hcy after quantitative reductive
cleavage of all disulﬁde bonds, and total glutathione (GSH) were
assayed by using the ﬂuorimetric high-performance liquid chromatog-
raphy method as previously described [12]. The inter- and intra-assay
coefﬁcients of variation for mean tHcy level were 4.2% and 6.3%,
respectively, and the linearity was from 1 to 100 μM [13]. Serum insulin
was assayed by ELISA (Rat Insulin Elisa, cat. 10-1124-01, Mercodia,
Uppsala, Sweden) [14].
2.3. CBS enzyme activity assays
Determination of CBS activity was assayed on 400 μg of total
proteins obtained from liver samples, as described [15]. Proteins were
incubated for 1 h at 37 °C with 1 mM of propargylglycine, 0.2 mM of
pyridoxal phosphate, 10 mM of L-serine, 10 mM of DL-Hcy, 0.8 mM of
SAM, using DTNB (5,5′-dithiobis-(2-nitrobenzoic acid)) based-assay.
All the chemical products were obtained from Sigma (Sigma-Aldrich,
France).
2.4. Data analysis
Statistical analysis was done with one-way ANOVA followed by
Student's unpaired t-test using Statview software. In both cases,
Student–Newman–Keuls tests were used for multiple pairwise com-
parisons. The results are expressed asmean±SD. Data were considered
signiﬁcant when pb0.05.3. Results and discussion
3.1. Body weight and metabolic parameters in GK rats as a function
of age
As previously described [10], male GK rat body weights were
signiﬁcantly lower compared to age-matched Wistar rats (Fig. 1A).
Circulating glucose levels were similar in GK andWistar rats at 2 weeks
of age (Fig. 1B), but signiﬁcantly increased in GK rats from 1 month of
age (weaning) (Fig. 1B). Indeed, GK rats become hyperglycemic around
weaning, when the diet shifts from lipid-enriched maternal diet to
carbohydrate-enriched laboratory chow [16].
In 2-week-old GK rats, basal insulinemia was signiﬁcantly
decreased (Fig. 1C). However, because GK neonates exhibit a transient
increase in whole body insulin sensitivity as previously described
[10], they stay normoglycemic until around weaning. Then, GK rats
displayedmildly elevated but not statistically signiﬁcant insulin levels
at 1 month of age and the hyperinsulinemia became statistically sig-
niﬁcant at 2 and 3 months of age, once insulin multi-organ resistance
and especially liver insulin resistance has been established [11,17].
Thus, in addition to HFS-fed rats and ZDF rats, GK rats appeared to be a
suitable but nonobese model to analyze Hcy metabolism in associa-
tion with alterations of glucose metabolism.
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Fig. 2A shows that GK plasma tHcy levels were only about 45% of
that found in age-matched Wistar rats in both the prediabetic and
diabetic periods. These low plasma tHcy levels are in agreement with
those described in both type 1 STZ-induced diabetic rat model [18]
and spontaneous type 2 diabetic obese ZDF rats [8].
From the prediabetic stage onwards (Fig. 2B), GK rat also showed
a falling trend in plasma GSH levels, the effect being only signiﬁcant
at 2 weeks and 3 months of age. GSH is the most abundant low-
molecular-weight thiol and plays a key role in the cellular defense
against oxidative stress. GSH is a reference of antioxidant and its
antiatherogenic properties have been demonstrated in humans and
rodents [19,20]. Here, it should be underlined that decreased plasma
GSH levels are indicative of a compromise protection against oxidative
stress, which is already present in prediabetic GK animals [21].
The hepatic activities of several enzymes involved in the
remethylation and transsulfuration pathways that play a role in the
removal of Hcy were found to be increased in ZDF rat liver [8].
Previous results emphasized a direct effect of insulin in repressing
CBS expression in both human and rat cultured hepatocytes [22].
Therefore, to examine whether the lowering of GK rat plasma HcyFig. 2. Age-dependent changes in plasma Hcy and GSH levels, and relative hepatic
CBS activity. Hcy (A) and GSH (B) levels were determined in plasma. (C) CBS activity
assay was performed on extracts from liver of individual rats. CBS activity values
are normalized from age-matchedWistar rats. *pb0.05, **pb0.005, ***pb0.0005 versus
age-matched Wistar group.levels, reﬂecting cellular and mainly liver production, could result
from increased Hcy catabolism through the ﬁrst step of the
transsulfuration pathway, we measured the CBS enzyme activity.
Given that the majority of dietary methionine is metabolized in the
liver, which contributes to much of the plasma Hcy levels, we
analyzed the hepatic enzyme activity [23]. Fig. 2C shows that the
hepatic CBS activity was signiﬁcantly elevated in GK versus Wistar
rats and, once again, the effect was present from the prediabetic
stage onwards. Thus, low plasma tHcy levels were associated with
increased hepatic CBS enzyme activity in GK rat. However, increased
CBS activity does not imply increased transsulfuration ﬂux. This ﬂux
is determined by the rate at which methionine enters into hepatic
metabolism, which will be largely determined by dietary methionine
consumption. In the experimental mouse, hyperhomocysteinemia
is induced by methionine-enriched diet, and increased plasma Hcy
levels are accompanied by proportional increased GSH levels, without
modiﬁcation of cysteine and cysteinylglycine levels [24]. The major
effect of increased CBS activity is to decrease the steady-state Hcy
concentration at which transsulfuration occurs and then contributes
to the decreased plasma Hcy level. Therefore, decreased circulating
GSH levels may reﬂect decreased circulating Hcy levels in GK rats.
Similar data demonstrate low plasma tHcy levels with elevated
hepatic CBS activity in 3 different rat models of diabetes, STZ-induced
type 1 diabetes [18] and type 2 diabetes, either obese ZDF [8] or
nonobese GK rats (the present study). Thus, the association between
low plasma tHcy levels and high CBS activity does not depend on the
type of diabetes and the presence of obesity and is observed during
the short period of prediabetes in both type 2 models.
The repression of hepatic CBS expression and activity by insulin
has been demonstrated in STZ-induced type 1 (insulin-dependent)
diabetic rats [18,22]. In this model, increased hepatic CBS enzyme
activity was associated with elevated CBS mRNA expression and
insulin treatment normalized hepatic CBS expression and activity.
Type 2 diabetes is characterized by relative lack of insulin and/or the
resistance to the action of insulin. Insulin resistance is a multisite
dysfunction that involves, in particular, the liver [25]. Insulin signaling
in liver is critical in regulating glucose homeostasis and maintaining
normal hepatic function. At 1 month of age, GK rats already exhibit
increased hepatic glucose production speciﬁcally linked to early
liver insulin resistance. These data highlight a possible primary role
of the liver defect, and not simply a late consequence of chronic
hyperglycemia [26]. Thus, the lack of functional insulin or decreased
insulin sensitivity (insulin resistance) in the liver is probably at
play very early, during prediabetes in both the ZDF and GK type 2
models, resulting in increased hepatic CBS activity and low plasma
Hcy levels. Indeed, during the prediabetic stage, GK rats are mostly
characterized by very low insulin levels, while ZDF rats already exhibit
insulin resistance concomitant with hyperinsulinemia [8]. After
diabetes onset, GK rats exhibit progressive hepatic insulin resistance
and hyperinsulinemia [17], while ZDF rats become hypoinsulinemic in
addition to being insulin resistant [8]. Therefore, the lack of insulin
or the resistance to insulin action rather than hyperglycemia appear to
increase hepatic CBS activity and consequently decrease plasma Hcy
levels.
Because of anti-inﬂammatory effects of insulin [27], decreased
insulin levels in GK rats from end of fetal life onwards [28] might be
partly responsible for various neonatal oxidative stress-related signs,
like oxidized state of GSH in red blood cells associated with low
circulating GSH and elevated chemokine levels, and high islet ROS
concentration and alterations in GSH- and thioredoxin-related gene
expression [21]. We suggest that early insulin deﬁcit may cause
systemic and tissue oxidative stress in GK rats. This hypothesis is
in agreement with 1) the situation of prediabetic insulin-resistant
(i.e., with a relative lack of insulin) ZDF rats and 2) the ‘unexpected’
inverse relationship between insulin resistance and serum Hcy in
healthy subjects [6]. Thus, hypohomocysteinemia associated with low
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humans and rodents [19,20]) rather than hyperhomocysteinemia
might be a risk factor for CVD in insulin resistance and diabetes in
humans and rodents.
By contrast, hyperhomocysteinemia in type 1 and type 2 diabetic
patients appears to be dependent on the presence of nephropathy
[29,30]. GK rat does not spontaneously develop kidney disease.
However, secondary injurious mechanisms such as hypertension
induces progressive nephropathy [31]. By contrast, long-term (from
6 months to 2 years) HFS-fed rats, which are obese, normoglycemic,
hyperinsulinemic, and insulin resistant, display hyperhomocysteinemia
and lower hepatic CBS enzyme activity and mRNA expression than
normally fed rats [7]. These HFS-fed rats exhibit hypertension, and their
hyperhomocysteinemia probably result from kidney alterations which
develop rapidly after a fewweeks of diet [32,33]. Altered CBS activity in
HFS-fed rat kidney may cause hyperhomocysteinemia and diminish
hepatic CBS activity [34]. Accordingly, hyperhomocysteinemia in obese
and/or diabetic patients might more probably reﬂect kidney alteration.
In conclusion, the spontaneous nonobese type 2 diabetic GK rat,
characterized by an early deﬁcit in functional beta-cell mass, shows
decreased levels of circulating Hcy and a falling trend in its major
byproduct antioxidant GSH from the prediabetic stage onwards.
Concomitant increased hepatic CBS activity emphasizes the role of
insulin in Hcy and antioxidant GSH metabolism.
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